Background-The risk of myocardial infarction (MI) is elevated in people with diabetes mellitus (DM) compared with non-DM counterparts. The aim of this study was to compare population trends in the incidence of hospitalized MI and coronary heart disease (CHD) in adults with and without DM. Methods and Results-All incident hospitalized MI and CHD events were identified from whole-population hospital data in Western Australia for 1998 to 2010. Annual age-standardized MI and CHD incidence rates were calculated for people with and without DM aged 35 to 84 years and age-adjusted trends estimated from Poisson regression. There were 26 610 incident MI and 56 142 incident CHD cases during the study period. MI incidence rates fell in men (−2.9%/y; 95% confidence interval [CI], −3.7 to −2.1) and women (−3.8%/y; 95% CI, −4.8 to −2.1) with DM, representing overall reductions of 35% and 43% respectively, with comparable reductions in incident CHD. Downward trends in MI incidence in those with DM were most apparent in 55-to 84-year olds. In adults without DM, there was no decline in MI incidence but a small significant decrease in incident CHD (men, −1.5%/y; 95% CI, −1.8 to −1.2 and women, −1.3%/y; 95% CI, −1.8 to −0.9). Incidence rate ratios for MI in men with versus without DM declined from 4.5 (95% CI, 4.2-4.8) to 3.1 (95% CI, 2.9-3.3) and from 6.0 (95% CI, 5.4-6.6) to 3.8 (95% CI, 3.5-4.1) in women between 1998 and 2010. Conclusions-There have been significant reductions in incidence rates of MI and CHD in adults with DM between 1998 and 2010; however, the excess risk of MI incidence remains 3 to 4× greater in people with DM. (Circ Cardiovasc Qual Outcomes. 2014;7:708-717.)
T he risk of cardiovascular disease (CVD) in people with diabetes mellitus (DM) is 2 to 4× greater than in people without DM. 1, 2 Better treatment of DM and associated CVD risk factors may counter this elevated risk of macrovascular complications. Declining rates of first myocardial infarction (MI) and coronary heart disease (CHD) among people with DM are an indicator of improved treatment and primary prevention efforts, yet temporal trend data are scarce.
Major advances in medical therapies and cardiovascular prevention have contributed to long-term declines in CHD mortality and MI incidence; however, the downward trajectory of these trends may be impacted because of the increasing prevalence of DM and obesity. 3 In Western Australia (WA), the impact of troponin testing on the diagnosis of MI has led to an attenuation of declines in MI rates, 4 although hospitalized CHD incidence and recurrence rates have continued to fall. 5 These differences highlight the necessity of understanding trends across both disease groupings.
There are limited international and no Australian data showing long-term population trends in MI and CHD incidence separately for patients with and without DM. Data from European populations are equivocal as to whether MI incidence has declined in people with DM. 6, 7 The Framingham Heart Study has shown a long-term reduction in CVD incidence in people with DM, 8 but an increasing population attributable risk, which indicates a growing impact of DM relative to other risk factors. 9 The prevalence of DM has increased in the past decade in WA to 6.5%, 10 consistent with global trends. 11 Clinical trial evidence supports a greater focus on cardiovascular risk management for people with DM, 12 in tandem with improving glycemic control at an individual level. 13 Changing DM epidemiology including decreasing age at diagnosis, 14 longer duration, and improved survival for those with DM 15 means that the impact of these factors on the onset of MI in people with DM is poorly characterized. We therefore analyzed temporal trends in incidence rates of hospitalized MI and CHD between 1998 and 2010 in adults with and without DM. Second, we determined whether the risk of incident MI and CHD in people with versus without DM changed during this period.
Methods

Data Source
The population of WA was 2.3 million in 2010 16 and is representative of the Australian population in demographic and health economic indicators. 17 WA has a mixed public and private health system. The major tertiary hospitals are situated in the capital city, Perth, where the majority of acute coronary care and all invasive revascularization services are provided. Data for this study were obtained from the Hospital Morbidity Data System and Mortality Registrations, with links established through the WA Data Linkage System. This system centrally links core health administrative data sets by probabilistic matching on key variables (name, sex, date of birth, and address) with manual checking of uncertain links, and >99% accuracy reported for this process. 18 Data available included hospital inpatient information on patient demographics, principal diagnosis at discharge, secondary diagnoses, and inpatient procedures. The data set contained all CVD and DM morbidity and death records for patients aged 35 to 84 years from 1985 to 2010. Approval for this study was obtained from the ethics committees of The University of Western Australia and the WA Department of Health.
Identification of Incident MI and CHD
All patients admitted to hospital in WA between 1998 and 2010 with a principal discharge diagnosis of MI (International Classification of Diseases-Ninth Revision [ICD-9]-Clinical Modification 410; ICD-10-Australian Modification I21, I22) were identified. Incident MI events were defined as those with no prior MI admissions recorded in the principal or 20 secondary diagnosis fields using a fixed 13-year clearance period from each MI admission, which would correctly identify the majority of prior MI events. 19 The validity for identifying MI in linked hospital data has been tested in WA by validating MI recorded in hospital morbidity data against an algorithm based on American Heart Association criteria for MI diagnosis, with clinical data derived from medical and pathology records. 20 Decreasing sensitivity in the older age group was the reason for exclusion of >85-year olds. Patients presenting with MI who died in the emergency department were not included in the study. Incident CHD events were similarly identified from the principal diagnosis field and included hospitalization for any of MI, unstable or stable angina, or other acute or chronic CHD (410-414, I20-I25), where there was no CHD admission coded in the previous 13 years.
Identification of DM Status
DM was identified from any diagnosis field in the linked data set (ICD-9-CM 250, ICD-10-AM E10-E14). Incident MI and CHD cases were classified as having DM where there was ≥1 hospital admission in the 13 years before, or in the 28 days after, the incident admission. This method of defining DM status was evaluated by comparing DM recorded in hospital morbidity data with DM identified from medical records for patients with CHD in 1998 and 2002 to 2004. When DM status was identified from the index CHD admission only, sensitivity was significantly lower in the later period compared with 1998. The use of an extended lookback improved the accuracy of identifying DM (sensitivity, 93% and 90% in 1998 and 2002 to 2004, respectively; positive predictive value, 92% in both periods). 21
Patient Characteristics
Baseline characteristics and comorbidities for patients with incident MI and CHD were identified from the linked data set using all diagnosis fields. A 13-year lookback period including each incident event was used to identify hypertension (ICD-10-AM I10-I15/ICD-9-CM equivalent), heart failure (I50), atrial fibrillation (I48), prior stroke (I60-I64), peripheral arterial disease (I70-I79), chronic kidney disease (Australian Institute of Health and Welfare definition), 22 chronic obstructive pulmonary disease (J40-J47), and cancer (C00-D48). Patients were identified as undergoing a revascularization procedure (percutaneous coronary intervention or coronary artery bypass grafting) where it was recorded on or within 30 days of the incident MI admission date in any of the 11 procedure fields.
Patients with incident MI with admissions for angina or other acute or chronic ischemic heart disease (ICD-9 411-414, ICD-10-AM I20, I23-I25) in the 13 years before the incident MI were classified with prior CHD history. This excluded admissions in the 28 days immediately preceding the incident admission, as these were transfers or deemed to be related to the incident event. Patients with incident MI with prior percutaneous coronary intervention or coronary artery bypass grafting were similarly identified. Patients were classified as having ST-segment-elevation MI (STEMI) according to ICD-10-AM codes I21.0-I21.3.
Statistical Analysis
All analyses were conducted separately by sex. Trends in patient characteristics were assessed separately for patients with and without DM from unadjusted linear and logistic regression models for continuous and categorical variables, respectively, and similarly for differences in the overall prevalence of characteristics between patients with DM and without DM.
Annual incidence rates of MI were calculated using counts of incident MI in each group for each calendar year as the numerator and the at-risk population in each year for the denominator. To estimate the at-risk population, annual counts of prevalent diabetic cases were calculated by identifying people with any hospital admission for DM using a 13-year lookback from 30th June in each study year and who were alive at this date. People with a prior history of MI were excluded from counts of annual DM prevalence. The annual counts of prevalent DM cases with no MI history were the denominator for MI incidence rates in people with DM. For rates in the non-DM population, the
WHAT IS KNOWN
• The risk of a myocardial infarction is 2 to 4× greater in people with diabetes mellitus (DM) than in those without. • Trends in the incidence of myocardial infarction and coronary heart disease are an indicator of the effect of prevention approaches, yet there are limited data detailing these trends in people with DM at a population level.
WHAT THE STUDY ADDS
• There was a substantial reduction in incidence rates of hospitalized myocardial infarction and coronary heart disease in men and women with DM in a whole-population setting during a 13-year period. • In contrast, the decline in the incidence of myocardial infarction in people without DM was limited; however, incidence rates of hospitalized coronary heart disease fell during the same period. • These results highlight the likely impacts of changes in the management of people with DM at a population level. Despite these trends, the risk of an incident myocardial infarction remained ≈2× higher in people with versus without DM at the end of the study period.
prevalent DM population was subtracted from the whole WA population in each study year. 16 The same method was used to determine the at-risk population for CHD incidence. Rates were standardized using the direct method by 5-year age group for overall and age-specific rates, with the population of WA in 2010 as the standard population. Annual percentage changes were estimated using Poisson regression, adjusting for 5-year age group, and calculated from the exponential of the β-coefficient for calendar year. Annual age-adjusted incidence rate ratios (IRR) in patients with versus without DM were calculated and are presented for 1998 and 2010. The age-adjusted trend in IRRs was estimated for the whole study period, using a model that included 5-year age group, DM status, calendar year, and an interaction term (DM status×calendar year). Statistical significance levels were set at P<0.05 and SAS v9.4 (Cary, NC) used for all statistical analyses. Tables 1 and 2 show the trends in patient characteristics and comorbidities separately for patients with and without DM at incident MI. There were 26 610 incident MI admissions in WA from 1998 to 2010, with DM cases comprising 22.8% in men and 29.6% in women. The mean age at first MI presentation was higher in men with DM but not in women relative to their non-DM counterparts. There was no significant fall in mean age during the study period in patients with DM, whereas it decreased in people without DM (men, −0.6 years; P<0.05 and women, −2.2 years; P<0.0001). Indigenous Australians were significantly over-represented in men and women with versus without DM (P<0.0001). Comorbidity levels at incident MI were significantly higher in patients with DM (P<0.05 for all overall comparisons with non-DM patients; Tables 1 and 2 ). Hypertension increased in both groups (P<0.0001), and the proportion of patients with heart failure was 2-to 3-fold higher in those with DM compared with those without DM, although the prevalence fell in both. Trends in concomitant chronic kidney disease were contrasting, with significant increases in patients with DM (20.4%-26.2% in men and 22.0%-29.3% in women), whereas falling in patients with no DM (8.8%-5.6% in men and 9.2%-6.4% in women). Prior CHD history was increasingly more prevalent in patients with DM. The proportion of patients with incident MI undergoing percutaneous coronary intervention increased significantly, although levels at the end of the study remained higher in non-DM men (62.9% versus 46.2%) and women (42.9% versus 35.8%). There was a significant reduction in the recording of STEMI in men and women in both groups (P<0.0001 for all groups).
Results
Patient Characteristics and Comorbidities
When incident hospitalized CHD was analyzed, 56 142 cases were identified. Compared with incident MI cases only, a lower proportion were classified with DM (18.0% in men and 21.7% in women; Table I in the Data Supplement). Mean age at incident CHD was on average 2 to 3 years younger than observed for incident MI. Trends in characteristics and comorbidities were generally similar to those seen for incident MI, except for a significantly decreasing proportion of patients with DM and without DM undergoing coronary artery bypass grafting at incident admission ( Table I in 
Age-Standardized Trends
Age-standardized rates of incident MI declined significantly in patients with DM ( Figure 1 ), representing an average age-adjusted annual decline of −2.9% (95% confidence interval [CI], −3.7 to −2.1) in men and −3.8% (95% CI, −4.8 to −2.1) in women (Table 3) . Assuming a log-linear decline, the age-adjusted risk of an incident MI in patients with DM in 2010 compared with 1998 was 0.65 (95% CI, 0.55-0.76) in men and 0.57 (95% CI, 0.46-0.71) in women, representing overall falls of 35% and 43%, respectively. Incidence rates for MI in patients without DM were unchanged, and the equivalent age-adjusted risk for the study period in non-DM patients was 0.97 (95% CI, 0.89-1.05) and 0.95 (0.84-1.08) in men and women, respectively.
Incidence rates of CHD fell significantly in patients with DM (−3.8%/y in men and −4.7%/y in women) and also declined significantly in the non-DM group, although to a lesser extent (Table 4; Figure 2 ).
Age-adjusted IRRs for MI in men with versus without DM fell from 4.5 (95% CI, 4.2-4.8) in 1998 to 3.1 (95% CI, 2.9-3.3; P<0.0001 for trend) by 2010. There was a similar reduction in IRR in women with DM (6.0; 95% CI, 5.4-6.6 in 1998 and 3.8; 95% CI, 3.5-4.1; P<0.0001) in 2010 (Table 3 ). There were similar reductions in the IRR for CHD in patients with versus without DM during the study (Table 4 ).
Age-Specific Trends
Incidence rates of MI fell significantly in patients with DM in 55-to 69-and 70-to 84-year olds, with average annual declines of 3% to 5% across each age and sex grouping ( Table 3) . For those without DM, significant reductions were only apparent in 70-to 84-year olds (men, −1.3%/y and women, −1.5%/y). Rates in the 35-to 54-year-old age group with DM were unchanged across the study period and increased in the non-DM group by 1.1%/y (95% CI, +0.3 to +1.9) in men and 2.3%/y (95% CI, +0.5 to +4.2) in women (Table 3 ; Figure 3 ). Age-specific trends for CHD incidence were in contrast to the MI trends, with significant declines in all age groups except for 35-to 54-year-old women without DM (+1.1%/y; 95% CI, +0.1 to +2.1). Incidence rates were high in 35-to 54-year olds with DM, with age-specific IRRs for MI and CHD in those with DM 2-to 3-fold higher in the 35-to 54-year age group relative to older age groups ( Figure 3A and 3C ). There was a reduction in IRRs between 1998 and 2010 in all age groups, although not significantly so for 35-to 54-year-old men (P=0.23 for incident MI and P=0.42 for incident CHD; Tables 3 and 4 ).
Discussion
We found a substantial reduction in MI incidence rates of 35% in men and 43% in women with DM during a 13-year period in a whole-population setting. This finding is supported by concordant falls in incident hospitalized CHD in people with DM. These trends occurred despite higher levels of comorbidity and some adverse risk factor trends in these patients. However in people without DM, incident MI rates were unchanged and CHD incidence reduced at a lesser rate than in patients with DM. The age-adjusted risk of an incident MI in adults with versus without DM fell by nearly half, although some of the improvement could be attributed to the limited decline in MI incidence rates in non-DM patients. Overall trends in patients with DM were driven by reductions in rates in 55-to 84-year olds, whereas only 70-to 84-year olds demonstrated declining rates in the non-DM group.
Uniquely, we have shown that population incidence rates of MI and CHD have fallen more quickly in adults with versus without DM. There is evidence that people with DM have experienced smaller or similar improvements in mortality 15, 23 ; however, data are limited for trends in nonfatal events. Our results are consistent with a declining 10-year risk for developing CHD in people with DM in the National Health and Nutrition Examination Survey (NHANES) cohort, 24 and the Framingham Heart Study has demonstrated comparable reductions in CVD incidence in people with and without DM during a 50-year period. 8 Contrasting trends are reported from European populations, with MI incidence unchanged in those with DM in a Swedish cohort 7 but increasing in men and decreasing in women with DM in a German setting. 6 Differing upper age ranges (64 and 74 years, respectively) may have contributed to these contrasting findings. Our study showed that MI incidence in people with DM has declined in WA, concurrent with an increasing population prevalence of DM. However, if the increase is mainly because of the inclusion of less severe and lower risk cases, this may explain some of the declining MI incidence in people with DM. Our analysis of CHD incidence, which provides a broader representation of disease incidence and prevention efforts, confirms a real downward trend in both men and women with DM.
Our findings occurred during a period of major change in the management of DM. Clinical trials have shown that intensive glycemic control results in significant reductions in microvascular outcomes. 13 Evidence is now emerging that this approach also reduces macrovascular outcomes, 25 with patients with DM intensively treated with sulfonylurea/insulin or metformin demonstrating a 15% and 33% reduction, respectively, in the 10-year risk of MI. 26 In Australia, increasing rates of oral hypoglycemic use, particularly metformin, are reported in national statistics. 27 Reductions in HbA 1c in type 2 diabetics have been shown in the local Fremantle Diabetes Study 28 and during a 4-year period in the Fenofibrate Intervention and Event Lowering in Diavetes (FIELD) study, 29 but these changes were associated with intensification of glycemic therapy. This changing management approach is a potential contributor to the favorable trends seen in people with DM in our population.
Concomitantly there has been a shift toward more aggressive control of cardiovascular risk factors in patients with DM. 12, 30 In Australia, guidelines were modified in 2003 to recommend pharmacological treatment for patients with DM and no manifest CVD if blood pressure was >130/85 mm Hg and total cholesterol >3.5 mmol/L. 31 National prescribing criteria were changed in 2006 to subsidize statins for all patients with DM aged ≥60 years irrespective of lipid levels and for lower risk patients with DM where total cholesterol was >5.5 mmol/L. 32 Modeling of these changes suggests that provision of statins to normolipidemic patients with DM would prevent >3200 major cardiovascular events during a 4-year period. 33 Improving cardiovascular risk management in patients with DM is suggested by a national audit of specialist DM centers between 1998/1999 and 2011, which showed an increase in the use of antihypertensive (36%-57%) and lipid-lowering therapies (19%-60%) in people with DM 34 and an increasing proportion of patients with DM in primary care meeting blood pressure and lipid targets. 35 These data may provide indirect evidence of the effects of improving cardiovascular risk factor management in this patient group.
The difference between trends in MI and CHD incidence in non-DM patients may be related to changes in the diagnostic algorithm for MI. The introduction of troponin testing for MI diagnosis attenuated declines in MI incidence 36 and hospitalization rates 4 because of the increased number of non-STEMI cases diagnosed. Although the coding of MI type in administrative data has not been fully tested, we identified similar large declines in the proportion of MI recorded as STEMI in adults with and without DM. Paradoxically, additional non-STEMI cases detected by troponin testing are more often in people with DM, 37 and people with DM in the general population are more likely to have elevated levels of troponin because of the presence of subclinical microvascular disease. 38 This suggests that the trends in patients with DM presented in the current study may actually represent an attenuation of larger downward trends in MI incidence. The increasing detection of non-STEMI could also affect the identification of the at-risk populations, leading to a lower risk MI-free population in the later part of the study. This effect may be greater in the DM population; however, the trend in CHD incidence, where the impact of troponin is reduced, lends weight to a real decline in MI incidence in patients with DM.
The reduction in MI incidence in patients with DM occurred in the context of an increasing proportion with previously diagnosed CHD. Although this might reflect the greater likelihood of hospitalization in diabetics, 39 it is more likely because of increased diagnosis and receipt of treatment for CHD in these patients. For example, the proportion of patients with DM undergoing revascularization before first MI was double that of non-DM patients. Disparity in the use of percutaneous coronary intervention after incident MI in DM versus non-DM patients remained apparent. This has been noted previously in registry data 40 and may persist because of the perceived higher risk profile of these patients, particularly for women. DM is also a major risk factor for heart failure in people with acute CHD 41 and was found to be twice as common in patients with DM and incident MI, but declined significantly during the period. In contrast, chronic kidney disease in patients with DM and first MI increased to ≈30% by the end of the period, 5× higher than in patients with MI without DM, highlighting targets for treatment and reducing risk in these patients. Lower levels of guideline-recommended pharmacological and invasive treatments continue to be reported for patients with DM even after manifest CVD. 40, 42 We have shown previously that incidence rates of MI have increased in women and remained unchanged in men aged 35 to 54 years, 43 consistent with adverse trends in younger people elsewhere. 44 Although MI incidence rates were unchanged in 35-to 54-year olds with DM and increasing in those without DM, encouragingly, CHD incidence declined. The exception was in women without DM where rates increased. Notably there was a trend toward incident MI occurring at a younger age in this group. A possible explanation is that changes in prevalence of other risk factors such as smoking are associated with these trends; there may also be a higher proportion of undiagnosed diabetics because younger people have less contact with the health system, 39 or a higher threshold before diagnosis of type 2 DM is made in this age group. Further exploration of the impact of cardiovascular risk factors and the diagnosis and management of DM in younger people is needed to help understand these apparent incongruous trends.
Limitations
We have not included out of hospital deaths attributed to MI or CHD, as we were unable to ascertain the DM status for deaths with no prior hospitalization history from our data set. We have shown that trends would not be affected by the small degree of misclassification of DM status because of the use of an extended lookback period to determine DM status. 21 However, there may still be a degree of undiagnosed DM even after presentation to hospital, because of reluctance by doctors to label a patient in the acute setting with DM. This inclusion of patients with MI and DM in the non-DM group may overestimate rates in people without DM, but would only affect trends if there were changes in this practice over time. Information on comorbidities was obtained from hospitalization data, and therefore some cardiovascular risk factor data were not available. Smoking and dyslipidemia are poorly recorded in hospital morbidity data and were not included in our study. Changes in coding standards over time can also affect the accuracy of comorbidity recording, but this is reduced by the use of a lookback period to identify these conditions. DM prevalence is underestimated from hospital data because ascertainment of the at-risk DM population relies on a person with DM being hospitalized during the 13-year lookback period. Less severe cases of DM treated in the community are more likely to be misclassified as nondiabetic using this method. Therefore, the incidence rates calculated in this study may overestimate true rates in patients with DM because a smaller and higher risk population is used in the denominator. However, correct classification of the diabetic population is potentially greater than for other conditions because of the high hospitalization rates in these patients, for example, 80% of patients with DM identified from a local primary care DM register were admitted to hospital within 10 years of diagnosis. 39 If trends in hospital-identified DM prevalence are reflective of population-based DM trends, the use of this data source for calculating the at-risk population for incidence rates will provide reliable trend estimates. As a sensitivity analysis, we calculated age-adjusted trends for hospital-identified DM prevalence and compared this with state-based self-reported survey data 10 for 35-to 84-year olds. This was undertaken for 2003 to 2010 because of the availability of the survey data for that period. Similar upward trends in DM prevalence were seen for both data sources (average increase of 2%/y), showing that hospital morbidity data are a reasonable data source for obtaining denominators for population-based rates. However, comparison of these data sources for >85-year olds showed that this age group was over-represented in hospital relative to survey data, in contrary to the underestimation in other age groups, and confirmed the exclusion of this age group from our analysis.
Conclusions
This study has demonstrated substantial downward trends in incidence rates of hospitalized MI and CHD in adults with DM and a reduction in the excess risk associated with DM for these major cardiovascular events. These changes have occurred during a period of significant change in the treatment and CVD risk management for patients with DM, suggesting that such prevention approaches have translated positively from clinical trials and may be particularly effective in a whole-population setting. The attenuation of MI incidence rates in people without DM deserves further attention because of the sustained flattening of rates beyond the initial introduction of troponin assays. Importantly, we have shown that the limited improvements in MI incidence in young adults occur in people with and without DM, meaning that the impact of other clinical and risk factors needs to be considered to address these unfavorable trends.
